Cms-10434 #26 Aqm2018-cob

Centers for Medicare & Medicaid
Services
CMS eXpedited Life Cycle (XLC)

Medicaid and CHIP Program (MACPro)
AQM 2018 – Concurrent Use of Opioids
and Benzodiazepines (COB-AD) Core
Measure PRA document
Version 1.0
07/17/2018

Document Number: 433-QSSI_MACPro_COB-AD_PRA-D
Contract Number: HHSM-500-2007-00024I: HHSM-500-T0014

CMS XLC

Table of Contents

Table of Contents
1. (COB) Core Measure – Screenshots ...................................................................... 1
1.1
1.2
1.3
1.4
1.5
1.6
1.7

Are you reporting on this measure? ................................................................ 1
Measurement Specification ............................................................................. 1
Data Source .................................................................................................... 1
Definition of Population Included in the Measure ............................................ 2
Combined Rate(s) from Multiple Reporting Units ............................................ 3
Optional Measure Stratification ....................................................................... 4
Additional Notes/Comments on Measure (Optional) ....................................... 5

Appendix A:

Acronyms ......................................................................................... 6

List of Figures
Figure 1: Are you reporting on this measure? ................................................................. 1
Figure 2: Measurement Specification .............................................................................. 1
Figure 3: Data Source ..................................................................................................... 1
Figure 4: Definition of Population Included in the Measure ............................................. 3
Figure 5: Combined Rate(s) from Multiple Reporting Units ............................................. 3
Figure 6: Optional Measure Stratification ........................................................................ 4
Figure 7: Additional Notes/ Comment on Measure (Optional) ......................................... 5

List of Tables
Table 1: Acronyms .......................................................................................................... 6

AQM 2018 – Concurrent Use of Opioids and Benzodiazepines (COB-AD) Core Measure PRA document
Version 1.0
i

07/17/2018

CMS XLC
(COB) Core Measure – Screenshots

1. (COB) Core Measure – Screenshots
1.1

Are you reporting on this measure?

Figure 1: Are you reporting on this measure?

1.2

Measurement Specification

Figure 2: Measurement Specification

1.3

Data Source

Figure 3: Data Source

AQM 2018 – Concurrent Use of Opioids and Benzodiazepines (COB-AD) Core Measure PRA document
Version 1.0
1

07/17/2018

CMS XLC
(COB) Core Measure – Screenshots

1.4

Definition of Population Included in the Measure

AQM 2018 – Concurrent Use of Opioids and Benzodiazepines (COB-AD) Core Measure PRA document
Version 1.0
2

07/17/2018

CMS XLC
(COB) Core Measure – Screenshots

Figure 4: Definition of Population Included in the Measure

1.5

Combined Rate(s) from Multiple Reporting Units

Figure 5: Combined Rate(s) from Multiple Reporting Units

AQM 2018 – Concurrent Use of Opioids and Benzodiazepines (COB-AD) Core Measure PRA document
Version 1.0
3

07/17/2018

CMS XLC
(COB) Core Measure – Screenshots

1.6

Optional Measure Stratification

Note: Same N/D/R sets are displayed under each of the stratification categories.

Figure 6: Optional Measure Stratification

AQM 2018 – Concurrent Use of Opioids and Benzodiazepines (COB-AD) Core Measure PRA document
Version 1.0
4

07/17/2018

CMS XLC
(COB) Core Measure – Screenshots

1.7

Additional Notes/Comments on Measure (Optional)

Figure 7: Additional Notes/ Comment on Measure (Optional)

AQM 2018 – Concurrent Use of Opioids and Benzodiazepines (COB-AD) Core Measure PRA document
Version 1.0
5

07/17/2018

CMS XLC
(COB) Core Measure – Screenshots

Appendix A: Acronyms
Table 1: Acronyms
Acronym

Literal Translation

AQM

Adult Quality Measure

PRA

Paper Reduction Act of 1995

AQM 2018 – Concurrent Use of Opioids and Benzodiazepines (COB-AD) Core Measure PRA document
Version 1.0
6

07/17/2018